|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
DPP-4 inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Januvia
|
|
gptkbp:can_be_used_with
|
gptkb:simvastatin
gptkb:metformin
|
|
gptkbp:category
|
gptkb:unknown
Category B
|
|
gptkbp:class
|
antidiabetic agent
gliptin
|
|
gptkbp:clinical_trial
|
weight management
Phase III
glycemic control
|
|
gptkbp:contraindication
|
type 1 diabetes
diabetic ketoacidosis
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
oral tablet
100 mg once daily
|
|
gptkbp:effective_date
|
gptkb:2006
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
tablets
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sitagliptin
|
|
gptkbp:ingredients
|
sitagliptin phosphate
C16 H15 F6 N5 O
|
|
gptkbp:interacts_with
|
gptkb:digoxin
gptkb:warfarin
other antidiabetic drugs
furosemide
|
|
gptkbp:invention
|
gptkb:2022
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:lifespan
|
12.4 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:safety_features
|
risk of heart failure
risk of severe allergic reactions
monitor for pancreatitis
not for use in patients with type 1 diabetes
|
|
gptkbp:side_effect
|
headache
allergic reactions
joint pain
skin reactions
hypoglycemia
pancreatitis
nasopharyngitis
upper respiratory tract infection
|
|
gptkbp:traded_on
|
gptkb:Januvia
gptkb:Janumet
|
|
gptkbp:type_of
|
489461-35-5
|
|
gptkbp:bfsParent
|
gptkb:Saxagliptin
gptkb:Januvia
gptkb:Janumet
|
|
gptkbp:bfsLayer
|
6
|